Hiroaki Uchida

This inventor holds 22 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Cancer Therapy. Top assignees: University of Pittsburgh, Oki Electric Industry Co., Ltd., Daiichi Sankyo Company, Limited. Active years: 1987-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hiroaki Uchida. Retrieved from https://idiyas.com/inventor/hiroaki-uchida

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 3)

% Patents Active = 77.3

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 47(Granted Patents)

Location History:

Miyagi, JP (2004)
Yamanashi, JP (2003 - 2007)
Kanagawa, JP (2019)
Hachioji, JP (2019 - 2022)
Tokyo, JP (1987 - 2024)

Company Filing History:

8 out of 1,960

University of Pittsburgh

patents

5 out of 4,980

Oki Electric Industry Co., Ltd.

patents

4 out of 462

Daiichi Sankyo Company, Limited

patents

4. 2 out of 185

Kyorin Pharmaceutical Co., Ltd.

patents

5. 1 out of 707

Oki Semiconductor Co., Ltd.

patents

6. 1 out of 1,356

The University of Tokyo

patents

7. 1 out of 29

Universal Can Corporation

patents

Years Active: 1987-2025

Loading Chart...

Areas of Expertise:

Oncolytic Virus

Antibody-Drug Conjugates

Tumor Treatment

Claudin-6

HSV Vector

Pyrrolobenzodiazepine

Semiconductor Wafer

Integrated Circuit

Hemispherical Grains

Antimycotic Agents

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12350344 - Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate (2025-07-08),

2. 12263197 - Oncolytic virus for cancer therapy (2025-04-01),

3. 12246196 - Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines (2025-03-11),

4. 11920863 - Nozzle, drying device, and method for producing can body (2024-03-05),

5. 11883448 - Oncolytic HSV vector (2024-01-30),

6. 11628223 - Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines (2023-04-18),

7. 11583590 - Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor (2023-02-21),

8. 11419926 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2022-08-23),

9. 10576115 - Oncolytic HSV vector (2020-03-03),

10. 10328136 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2019-06-25),

11. 10201575 - Oncolytic HSV vector (2019-02-12),

12. 10188686 - Oncolytic HSV vector (2019-01-29),

13. 10172893 - Oncolytic HSV vector (2019-01-08),

14. 9593347 - Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-HSV receptors (2017-03-14),

15. 7601617 - Semiconductor wafer and manufacturing method thereof (2009-10-13),

Title: Hiroaki Uchida: Pioneering Innovations in Cancer Therapy

Introduction

Hiroaki Uchida, a prominent inventor based in Tokyo, Japan, is renowned for his groundbreaking contributions in the field of cancer therapy. With an impressive portfolio of 21 patents, Uchida is at the forefront of developing innovative medical solutions aimed at improving patient outcomes.

Latest Patents

Uchida's recent patents highlight his commitment to advancing cancer treatment methodologies. His work on an "Oncolytic virus for cancer therapy" focuses on developing a virus preparation incorporating an oncolytic herpes simplex virus (HSV). This preparation aims to achieve more effective cancer cell-killing activity compared to existing oncolytic HSVs. The invention specifically discusses an HSV with a receptor-retargeted gD mutation and a membrane fusion activity-promoting region on its genome, coupled with a method for utilizing this virus preparation in cancer treatment.

Another significant patent concerns "Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines." This innovation introduces novel derivative compounds and conjugates, alongside methods for their application. The compounds, categorized as alkyl benzene sulfonyl ureas, are particularly valuable in treating diabetes, showcasing Uchida's versatility in addressing multiple health issues.

Career Highlights

Throughout his career, Uchida has collaborated with prestigious organizations, enhancing his contributions to cancer research. Among his notable associations are the University of Pittsburgh and Oki Electric Industry Co., Ltd. His extensive experience has enabled him to push the boundaries of cancer therapy and related fields.

Collaborations

Uchida's work has been enriched by collaborations with esteemed colleagues, including Joseph C. Glorioso III and Justus B. Cohen. Their joint efforts have resulted in innovative solutions and advancements in the medical and pharmaceutical landscapes.

Conclusion

Hiroaki Uchida exemplifies the spirit of innovation in the medical field through his numerous patents and collaborative efforts. His recent developments in cancer therapy and related areas not only signify a leap forward in treatment options but also reflect his unwavering dedication to improving human health. As his research continues to evolve, the impact of his inventions is poised to benefit countless patients worldwide.

Profile summary based on public USPTO records.